Bright Minds Biosciences (TSE:DRUG) has released an update.
Bright Minds Biosciences, a trailblazer in CNS disorder treatments, is set to present their groundbreaking research at prominent scientific conferences and biotech events. The company will showcase its advancements in novel 5-HT2C agonist therapies, including BMB-101 for drug-resistant epilepsy and depression, aiming to capture the attention of the neuroscience community and potential investors.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
